Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Secondary Progressive Multiple Sclerosis (SPMS) Clinical Trial

Official title: Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)

Status Completed

Clinical Trial Summary

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

Clinical Trial Description

This is a non-interventional study, and as such there is no binding treatment strategy, diagnosis/treatment procedures or visit schedule. The investigator should administer Mayzent as labelled. Routine medical practice will apply to visit frequency and evaluation variables, and only these data will be collected by the sponsor as part of the study procedures. The investigator should record data in the applicable CRFs at every visit if possible. ;

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Neoplasm Metastasis
• Sclerosis
• Secondary Progressive Multiple Sclerosis (SPMS)

• NCT number: NCT04593927
• Study type: Observational
• Source: Novartis
• Status: Completed
• Start date: October 28, 2020
• Completion date: August 30, 2023